Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer July 14, 2022July 14, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: [Ad hoc announcement pursuant to Art. 53 LR] Roche’s…Roche's Kadcyla is the first targeted therapy…Pivotal Phase III data at ASCO show Roche’s…Roche’s inavolisib combination reduces the risk of…Roche announces positive Phase III results for…Data up to 8-years for Roche’s OCREVUS (ocrelizumab)…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
